Heat Biologics Inc. is a US biotechnology company focused on the field of cancer immunotherapy. This company’s cancer vaccine is called ImPACT, short for Immune Pan-Antigen Cytotoxic Therapy. ImPACT is in Phase II in NSCLC and bladder cancer.

ImPACT is a proposed cancer vaccine based on live, genetically-modified, irradiated human cells which secrete a broad spectrum of cancer-associated antigens as well as an immune adjuvant called gp96. Potential advantages of this product are use as an 'allogeneic', that is, 'off-the-shelf' immunotherapy, and its appplicability to a wide range of cancers. It is in phase II trials.

ImPACT originated in the late 1990s in work done at the University of Miami which showed that gp96, a heat shock protein resident in the endoplasmic reticulum could be made immunogenic if part of gp96 was replaced with the Fc portion of an IgG1 antibody to engineer a secretory form of gp96. In vivo gp96-Ig generated a strong CD8+ T cell response

ComPACT is a combination of a pan-antigen T cell priming vaccine and a T cell co-stimulator.

HS-410, also called vesigenurtacel-L, is currently in Phase II in Non-Muscle-Invasive Bladder Cancer (NMIBC), in combination with BCG. In Feb 2016 patient enrollment was paused (for lack of BCG).

HS 110, called viagenpumatucel-L, is in Phase II in NSCLC, in combination with cyclophosphamide. Another Phase I study is combining HS 110 with nivolumab and other checkpoint inhibitors.

Heat Biologics stock is traded on Nasdaq under the code HTBX. The company did its IPO on Nasdaq in mid-2013, with its stock commencing trading on 24 July 2013.

Heat Biologics' Chairman and CEO is Jeffrey Wolf, a serial Life Sciences entrepreneur who founded the company in 2008. Its Chief Scientific Officer is Dr. Jeff Hutchins.

Heat Biologics is headquartered in Durham, NC. Its office at 801 Capitola Drive is located near the I-40 about three miles to the southwest of Research Triangle Park and eight miles to the west of Raleigh–Durham International Airport.